Katz Jeffry A
Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, OH 44106-5066, USA.
J Dig Dis. 2007 May;8(2):65-71. doi: 10.1111/j.1443-9573.2007.00287.x.
Optimal care of the inflammatory bowel diseases, Crohn's disease and ulcerative colitis, requires a broad understanding of disease pathophysiology and therapeutic alternatives. The goals of therapy are accurate diagnosis and timely treatment to both induce and maintain a clinical remission and improve patient quality of life. Most patients can be adequately treated using a combination or aminosalicylates, antibiotics, and corticosteroids, though many patients with Crohn's disease will require immunomodulators, such as azathioprine or 6-mercaptopurine. The development of novel biologic therapies, particularly infliximab, have dramatically improved our ability to medically manage more severe Crohn's disease and ulcerative colitis patients. This review will focus on the medical management of inflammatory bowel disease in adults.
对炎症性肠病(克罗恩病和溃疡性结肠炎)的最佳治疗需要对疾病病理生理学和治疗选择有广泛的了解。治疗目标是准确诊断并及时治疗,以诱导和维持临床缓解并改善患者生活质量。大多数患者使用氨基水杨酸类药物、抗生素和皮质类固醇联合治疗即可得到充分治疗,不过许多克罗恩病患者需要免疫调节剂,如硫唑嘌呤或6-巯基嘌呤。新型生物疗法的发展,尤其是英夫利昔单抗,极大地提高了我们对更严重的克罗恩病和溃疡性结肠炎患者进行医学管理的能力。本综述将聚焦于成人炎症性肠病的医学管理。